{
    "id": 2436,
    "fullName": "EGFR T854A",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EGFR T854A lies within the protein kinase domain of the Egfr protein (UniProt.org). T854A has been associated with drug resistance (PMID: 19010870), and results in increased cell proliferation and cell viability as compared to wild-type Egfr in one of two cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 965,
                    "pubMedId": 19010870,
                    "title": "Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19010870"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "T854A",
    "createDate": "10/23/2014",
    "updateDate": "10/31/2019",
    "referenceTranscriptCoordinates": {
        "id": 135940,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55191809A>G",
        "cDna": "c.2560A>G",
        "protein": "p.T854A",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16642,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR T854A were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 2318,
                "profileName": "EGFR T854A"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16645,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR T854A were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 2318,
                "profileName": "EGFR T854A"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16643,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR T854A were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 2318,
                "profileName": "EGFR T854A"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16646,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR T854A were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 2318,
                "profileName": "EGFR T854A"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16644,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR T854A were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 2318,
                "profileName": "EGFR T854A"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14312,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR T854A were moderately sensitive to Alunbrig (brigatinib) in culture, demonstrating reduced cell growth (PMID: 29702287).",
            "molecularProfile": {
                "id": 6333,
                "profileName": "EGFR T854A EGFR L858R"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15007,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, EGFR T854A was identified as an acquired mutation conferring resistance to Iressa (gefitinib) in a patient with lung adenocarcinoma harboring EGFR L858R, which was supported by decreased response to Iressa (gefitinib) in cells expressing EGFR L858R and T854A in culture (PMID: 19010870).",
            "molecularProfile": {
                "id": 6333,
                "profileName": "EGFR T854A EGFR L858R"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 965,
                    "pubMedId": 19010870,
                    "title": "Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19010870"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2226,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of EGFR T854A decreased sensitivity of transformed cells expressing EGFR L858R to Tarceva (erlotinib) in culture (PMID: 19010870).",
            "molecularProfile": {
                "id": 6333,
                "profileName": "EGFR T854A EGFR L858R"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 965,
                    "pubMedId": 19010870,
                    "title": "Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19010870"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14310,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR T854A were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating decreased cell growth (PMID: 29702287).",
            "molecularProfile": {
                "id": 6333,
                "profileName": "EGFR T854A EGFR L858R"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14311,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR T854A were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating decreased cell growth (PMID: 29702287).",
            "molecularProfile": {
                "id": 6333,
                "profileName": "EGFR T854A EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14315,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR T854A were mildly resistant to Iressa (gefitinib) in culture (PMID: 29702287).",
            "molecularProfile": {
                "id": 6333,
                "profileName": "EGFR T854A EGFR L858R"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14303,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR exon19 del, and EGFR T854A were sensitive to treatment with Alunbrig (brigatinib) in culture, demonstrating reduced cell growth (PMID: 29702287).",
            "molecularProfile": {
                "id": 29956,
                "profileName": "EGFR exon 19 del EGFR C797S EGFR T854A"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14227,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR exon 19 del, and EGFR T854A demonstrated a decreased response to Gilotrif (afatinib) in culture when compared to Alunbrig (brigatinib) (PMID: 29702287).",
            "molecularProfile": {
                "id": 29956,
                "profileName": "EGFR exon 19 del EGFR C797S EGFR T854A"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14228,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR exon 19 del, and EGFR T854A were resistant to treatment with Tagrisso (osimertinib) (PMID: 29702287).",
            "molecularProfile": {
                "id": 29956,
                "profileName": "EGFR exon 19 del EGFR C797S EGFR T854A"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14226,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR exon 19 del, and EGFR T854A demonstrated a decreased response to Iressa (gefitinib) in culture when compared to Alunbrig (brigatinib) (PMID: 29702287).",
            "molecularProfile": {
                "id": 29956,
                "profileName": "EGFR exon 19 del EGFR C797S EGFR T854A"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14300,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L858R, and EGFR T854A demonstrated some resistance to Alunbrig (brigatinib) in culture (PMID: 29702287).",
            "molecularProfile": {
                "id": 29959,
                "profileName": "EGFR C797S EGFR T854A EGFR L858R"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14301,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L858R, and EGFR T854A demonstrated some resistance to Gilotrif (afatinib) in culture (PMID: 29702287).",
            "molecularProfile": {
                "id": 29959,
                "profileName": "EGFR C797S EGFR T854A EGFR L858R"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14297,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L858R, and EGFR T854A demonstrated resistance to treatment with Tagrisso (osimertinib) (PMID: 29702287).",
            "molecularProfile": {
                "id": 29959,
                "profileName": "EGFR C797S EGFR T854A EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14298,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L858R, and EGFR T854A demonstrated some resistance to Iressa (gefitinib) in culture (PMID: 29702287).",
            "molecularProfile": {
                "id": 29959,
                "profileName": "EGFR C797S EGFR T854A EGFR L858R"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14307,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR exon 19 del and EGFR T854A were moderately resistant to Iressa (gefitinib) in culture (PMID: 29702287).",
            "molecularProfile": {
                "id": 29981,
                "profileName": "EGFR exon 19 del EGFR T854A"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14305,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR exon 19 del and EGFR T854A were sensitive to treatment with Tagrisso (osimertinib), demonstrating reduced cell growth (PMID: 29702287).",
            "molecularProfile": {
                "id": 29981,
                "profileName": "EGFR exon 19 del EGFR T854A"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14309,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR exon 19 del and EGFR T854A were moderately resistant to Alunbrig (brigatinib) in culture (PMID: 29702287).",
            "molecularProfile": {
                "id": 29981,
                "profileName": "EGFR exon 19 del EGFR T854A"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14304,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR exon 19 del and EGFR T854A were sensitive to treatment with Gilotrif (afatinib), demonstrating reduced cell growth (PMID: 29702287).",
            "molecularProfile": {
                "id": 29981,
                "profileName": "EGFR exon 19 del EGFR T854A"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19900,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with an advanced solid tumor developed resistance to treatment with Tarceva (erlotinib) and via cell free DNA testing was found to harbor an EGFR exon 19 deletion, EGFR T790M, EGFR T854A, and CCDC6-RET (PMID: 31300450).",
            "molecularProfile": {
                "id": 34663,
                "profileName": "CCDC6 - RET EGFR exon 19 del EGFR T790M EGFR T854A"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17588,
                    "pubMedId": 31300450,
                    "title": "Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31300450"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2318,
            "profileName": "EGFR T854A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 6333,
            "profileName": "EGFR T854A EGFR L858R",
            "profileTreatmentApproaches": [
                {
                    "id": 4857,
                    "name": "EGFR Inhibitor 3rd gen",
                    "profileName": "EGFR T854A EGFR L858R"
                }
            ]
        },
        {
            "id": 29956,
            "profileName": "EGFR exon 19 del EGFR C797S EGFR T854A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29959,
            "profileName": "EGFR C797S EGFR T854A EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29981,
            "profileName": "EGFR exon 19 del EGFR T854A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34663,
            "profileName": "CCDC6 - RET EGFR exon 19 del EGFR T790M EGFR T854A",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135940,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55191809A>G",
            "cDna": "c.2560A>G",
            "protein": "p.T854A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}